Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Preferred Stock Liabilities (2021)

Historic Preferred Stock Liabilities for Amylyx Pharmaceuticals (AMLX) over the last 1 years, with Q4 2021 value amounting to $239.4 million.

  • Amylyx Pharmaceuticals' Preferred Stock Liabilities changed N/A to $239.4 million in Q4 2021 from the same period last year, while for Dec 2021 it was $239.4 million, marking a year-over-year change of. This contributed to the annual value of $239.4 million for FY2021, which is N/A changed from last year.
  • Amylyx Pharmaceuticals' Preferred Stock Liabilities amounted to $239.4 million in Q4 2021.
  • Over the past 5 years, Amylyx Pharmaceuticals' Preferred Stock Liabilities peaked at $239.4 million during Q4 2021, and registered a low of $239.4 million during Q4 2021.